Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.35 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15077401 | 0.90 | SMN1; SMN2 (0.33) | LMNASMN1; SMN2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL15077383 | 0.90 | SMN1; SMN2 (0.33) | LMNASMN1; SMN2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL15077404 | 0.90 | SMN1; SMN2 (0.33) | LMNASMN1; SMN2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL15078737 | 0.87 | PLA2G4B (0.33) | LMNASMN1; SMN2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL15074935 | 0.87 | PLA2G4B (0.33) | LMNASMN1; SMN2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL15078705 | 0.87 | PLA2G4B (0.33) | LMNASMN1; SMN2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL15077416 | 0.87 | ALDH1A1 (0.35) | LMNASMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL15077434 | 0.85 | TLR2 (0.33) | SMN1; SMN2ALDH1A1HPGDHTTTLR2 | |
| SCHEMBL3445836 | 0.83 | ALDH1A1 (0.42) | LMNASMN1; SMN2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL13035551 | 0.83 | ALDH1A1 (0.37) | LMNASMN1; SMN2CYP1A2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530452-B2 | Tricyclic boron compounds for antimicrobial therapy | MICURX PHARMACEUTICALS, INC. (KY) | 2013-09-10 | — | — | US | disclosed |
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | MICURX PHARMACEUTICALS, INC. (KY) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | TBCA, TBCB, BTD | LMNA 1003/4885SMN1; SMN2 1879/4885CYP1A2 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.